| Literature DB >> 33985445 |
Alemitu Beyene Gebre1, Tsegaye Alemayehu Begashaw1, Moges Desta Ormago2.
Abstract
BACKGROUND: Lower respiratory tract infection is a global problem accounting over 50 million deaths annually. Here, we determined the bacterial profile and antimicrobial susceptibility pattern of lower respiratory tract infections among adult patients attending at Tertiary Hospital, Southern Ethiopia.Entities:
Keywords: Antimicrobial susceptibility test; Culture-positive; Lower respiratory tract infection
Mesh:
Substances:
Year: 2021 PMID: 33985445 PMCID: PMC8120775 DOI: 10.1186/s12879-021-06151-2
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Sociodemographic characteristics of adult patients with lower respiratory tract infection at HUCSH, 2019
| Variables | Frequency | Percent (%) | |
|---|---|---|---|
| Sex | Male | 246 | 60.6 |
| Female | 160 | 39.4 | |
| Age (year) | 18–35 | 235 | 57.9 |
| 36–49 | 93 | 22.9 | |
| 50–64 | 51 | 12.6 | |
| > 65 | 27 | 6.7 | |
| Residence | Rural | 181 | 44.6 |
| Urban | 225 | 55.4 | |
| Education status | No formal education | 142 | 35.0 |
| 1–8 grade | 141 | 34.7 | |
| 9–12 grade | 70 | 17.2 | |
| Diploma & above | 53 | 13.1 | |
| Marital status | Single | 104 | 25.6 |
| Married | 302 | 74.4 | |
| Occupation | Farmer | 89 | 21.9 |
| Government | 43 | 10.6 | |
| Private | 93 | 22.9 | |
| Housewife | 112 | 27.6 | |
| Student | 52 | 12.8 | |
| Jobless | 17 | 4.2 | |
| Monthly income (Ethiopian birr) | < 1000 | 126 | 31.0 |
| 1000–2000 | 79 | 19.5 | |
| 2001–3000 | 118 | 29.1 | |
| 3001–5000 | 52 | 12.8 | |
| > 5000 | 19 | 4.7 | |
| No monthly income | 12 | 3.0 | |
Clinical characteristics of adult patients with lower respiratory tract infection at HUCSH, 2019
| Variables | Frequency | Percent (%) | |
|---|---|---|---|
| Cigarette smoking | Smoker | 33 | 8.1 |
| No smoker | 373 | 91.9 | |
| Alcohol drinking | Yes | 55 | 13.5 |
| No | 351 | 86.5 | |
| Crowded living condition | Yes | 52 | 12.8 |
| No | 354 | 87.2 | |
| History of the previous TB | Yes | 26 | 6.4 |
| No | 380 | 93.6 | |
| Heart disease | Yes | 34 | 8.4 |
| No | 372 | 91.6 | |
| Previous HIV screening | Positive | 26 | 6.4 |
| Negative | 167 | 42.1 | |
| Unscreened | 213 | 52.5 | |
Frequency of bacterial isolates identified from sputum specimen of an adult patient with community acquired LRTI at HUCSH 2019
| Isolates | Frequency | Percent (%) |
|---|---|---|
| 36 | 25.4 | |
| 25 | 17.6 | |
| 22 | 15.5 | |
| 21 | 14.8 | |
| 19 | 13.4 | |
| 9 | 6.3 | |
| 4 | 2.8 | |
| 6 | 4.2 |
aCitrobacter spp, S.pyogene and Enterococcus spp
Associated factors of culture-positive sputum sample of a patient with community acquired LRTI at HUCSH, 2019 (n = 406)
| Variables | Growth | COR (95%CI) | AOR (95%CI) | ||||
|---|---|---|---|---|---|---|---|
| Yes (%) | No (%) | ||||||
| Sex | Male | 87 (64.0) | 159 (58.9) | .807(.527–1.235) | 0.323 | ||
| Female | 49 (36.0) | 111 (41.1) | 1 | ||||
| Age (year) | 18–35 | 64 (47.1) | 171 (63.3) | 3.886 (1.712–8.821) | 0.001 | 3.856 (1.584–9.387) | 0.003* |
| 36–49 | 32 (23.5) | 61 (22.6) | 2.773 (1.151–6.677) | 0.023 | 3.136 (1.247–7.888) | 0.015* | |
| 50–64 | 24 (17.6) | 27 (10.0) | 1.636(.636–4.207) | 0.307 | 1.717(.637–4.631) | 0.285 | |
| > 65 | 16 (11.6) | 11 (4.1) | 1 | ||||
| Residence | Rural | 62 (45.6) | 119 (44.1) | 1 | |||
| Urban | 74 (54.4) | 151 (55.9) | .772(.703–1.609) | 0.772 | |||
| Educational status | No formal education | 48 (35.3) | 94 (34.8) | .703(.348–1.419) | 0.326 | .613(.194–1.931) | 0.403 |
| 1–8 grade | 53 (39.0) | 88 (32.6) | .596(.296–1.199) | 0.147 | .427(.146–1.248) | 0.120 | |
| 9–12 grade | 21 (15.4) | 49 (18.1) | .838(.378–1.857) | 0.663 | .556(.188–1.646) | 0.289 | |
| Diploma & above | 14 (10.3) | 39 (14.4) | 1 | ||||
| Marital status | Single | 24 (17.6) | 80 (29.6) | 1 | |||
| Married | 112 (82.4) | 190 (70.4) | .509(.305–.850) | 0.010 | .450(.207–.980) | 0.044* | |
| Occupation | Farmer | 31 (22.8) | 58 (21.5) | .689(.325–1.462 | 0.332 | 2.661(.841–8.413) | 0.096 |
| Government | 11 (8.1) | 32 (11.9) | 1.072(.428–2.687) | 0.882 | 6.303 (1.508–26.341) | 0.012* | |
| Private | 34 (25.0) | 59 (21.9) | .639(.304–1.345) | 0.239 | 2.425(.882–6.668) | 0.086 | |
| Housewife | 41 (30.1) | 71 (26.3) | .638(.309–1.315) | 0.223 | 2.048(.656–6.392) | 0.217 | |
| Student | 14 (10.3) | 38 (14.1) | .884(.264–2.965) | 0.842 | 3.192(.709–14.365) | 0.131 | |
| Jobless | 5 (3.7) | 12 (4.4) | 1 | ||||
| Monthly income | < 1000 | 38 (27.9) | 88 (32.6) | .463(.097–2.215) | 0.335 | .461(.083–2.551) | 0.375 |
| 1000–2000 | 26 (19.1) | 53 (19.6) | .408(.083–1.997) | 0.268 | .443(.076–2.578) | 0.365 | |
| 2001–3000 | 44 (32.4) | 74 (27.4) | .336(.070–1.606) | 0.172 | .310(.055–1.752) | 0.185 | |
| 3001–5000 | 17 (12.5) | 35 (13.0) | .412(.081–2.091) | 0.285 | .265(.043–1.61) | 0.150 | |
| > 5000 | 9 (6.6) | 10 (3.7) | .222(.038–1.298) | 0.095 | .060(.007–.526) | 0.011 | |
| No monthly income | 2 (1.5) | 10 (3.7) | 1 | ||||
| Cigarette Smoking | Smoker | 16 (11.8) | 17 (6.3) | 1 | |||
| No smoker | 120 (88.4) | 253 (93.7) | 1.984(.969–4.062) | 0.061 | 2.274(.810–6.385) | 0.119 | |
| Alcohol drinking | Yes | 24 (17.6) | 31 (11.5) | 1 | |||
| No | 112 (82.4) | 239 (88.5) | 1.652(.927–2.945) | 0.089 | 1.112(.468–2.642) | 0.809 | |
| Crowded living condition | Yes | 16 (11.8) | 36 (13.3) | 1 | |||
| No | 120 (88.2) | 234 (86.7) | 1.154(.615–2.164) | 0.655 | |||
| History of previous TB | Yes | 9 (6.6) | 17 (6.3) | 1 | |||
| No | 127 (93.4) | 253 (93.7) | 1.055(.457–2.432) | 0.901 | |||
| Chronic heart disease | Yes | 15 (11.0) | 19 (7.0) | 1 | |||
| No | 121 (89.0) | 251 (93.0) | 1.638(.804–3.334) | 0.174 | 1.530(.688–3.401) | 0.297 | |
| Previous HIV screening | Positive | 13 (9.6) | 13 (4.8) | 1 | |||
| Negative | 60 (44.1) | 107 (39.6) | .749(.486–1.154) | 0.190 | .524(.202–1.358) | 0.183 | |
| Unscreened | 63 (46.3) | 150 (55.6) | .420(.184–.957) | 0.039 | 1.301(.803–2.110) | 0.285 | |
CI Confidence Interval, OR Odds Ratio
Antibiotic susceptibility patterns of gram-positive bacterial isolates from lower respiratory tract infection at HUCSH, 2019
| Isolates | Pattern | Antibiotics (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CXT | TAT | AMP | CPR | COT | CLD | ERY | GN | PEN | CEF | CAF | ||
| S | 19 (90.6) | 3 (14.3) | 15 (71.4) | 9 (42.9) | 14 (66.7) | 10 (47.6) | 16 (76.2) | 9 (45.0) | ||||
| I | 1 (4.7) | 5 (23.8) | NR | 1 (4.8) | 2 (9.5) | 0 | 0 | 3 (14.3) | 2 (10.0) | NR | NR | |
| R | 1 (4.7) | 13 (61.9) | 5 (23.8) | 10 (47.6) | 7 (33.3) | 11 (52.4) | 2 (9.5) | 9 (45.0) | ||||
| S | 2 (22.2) | 8 (88.9) | 6 (66.7) | NR | 7 (77.8) | |||||||
| I | NR | 1 (11.1) | NR | NR | NR | 0 | 2 (22.2) | 0 | NR | NR | ||
| R | 6 (66.7) | 1 (11.1) | 1 (11.1) | 2 (22.2) | ||||||||
| S | 3 (100) | 3 (100) | 3 (100) | 3 (100) | NR | 3 (100) | 2 (66.7) | |||||
| I | NR | 0 | 0 | NR | NR | 0 | 0 | 0 | 0 | NR | ||
| R | 0 | 0 | 0 | 0 | 0 | 1 (33.3) | ||||||
| S | NR | 0 | NR | 1 (100) | 0 | 1 (100) | 0 | 0 | ||||
| I | 0 | 0 | 0 | 0 | 0 | NR | NR | NR | 0 | |||
| R | 1 (100) | 0 | 1 (100) | 0 | 1 (100) | 1 (100) | ||||||
| S | 19 (90.6) | 8 (23.5) | 3 (100) | 16 (72.0) | 9 (40.0) | 26 (76.5) | 19 (55.9) | 16 (76.2) | 19 (57.6) | 3 (100) | 0 | |
| I | 1 (4.7) | 6 (17.6) | 0 | 1 (4.5) | 2 (10.0) | 0 | 1 (2.9) | 3 (14.3) | 2 (6.0) | 0 | 0 | |
| R | 1 (4.7) | 20 (58.8) | 0 | 5 (22.7) | 11 (50.0) | 8 (23.5) | 14 (41.2) | 2 (9.5) | 11 (33.3) | 0 | 1 (100) | |
NR Not recommended, CXT Cefoxitin, AMP Ampicillin, CEF Cefepime, TAT Tetracycline, CPR Ciprofloxacin, COT Cotrimoxazole, ERY Erythromycin, PEN Penicillin, CAF Chloramphenicol, CLD Clindamycin, GN Gentamycin, S Sensitivity, I Intermediate, R Resistance
Antibiotic susceptibility pattern of gram-negative bacterial isolates of an adult patient with lower respiratory tract infection at HUCSH, 2019
| Isolates | Pattern | Antibiotics (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CEF | CAZ | CXT | TAT | CTR | AMP | AUG | CPR | COT | GN | IMP | ||
| S | 30 (83.3) | 13 (36.1) | 30 (83.3) | 15 (41.7) | 24 (66.7) | 9 (25.0) | 12 (33.3) | 33 (91.7) | 19 (52.8) | |||
| I | 0 | 4 (11.1) | 0 | 4 (11.1) | 4 (11.1) | 8 (22.2) | 4 (11.1) | 0 | 1 (2.8) | NA | NR | |
| R | 6 (16.7) | 19 (52.8) | 6 (16.7) | 17 (47.2) | 8 (22.2) | 19 (52.8) | 20 (56.6) | 3 (8.3) | 16 (44.4) | |||
| S | 23 (92.0) | 6 (24.0) | 17 (68.0) | 17 (68.0) | 16 (64.0) | |||||||
| I | 0 | 2 (8.0) | NR | NR | NR | NR | NR | 0 | NR | 4 (16.0) | 2 (8.0) | |
| R | 2 (8.0) | 17 (68.0) | 8 (32.0) | 4 (16.0) | 7 (28.0) | |||||||
| S | 17 (77.3) | 11 (50.0) | 18 (81.1) | 3 (13.6) | 14 (63.6) | 3 (13.6) | 5 (22.7) | 13 (59.1) | 10 (40.9) | |||
| I | 1 (4.5) | 2 (9.1) | 2 (9.1) | 5 (22.7) | 0 | 0 | 1 (4.5) | 0 | 1 (45.5) | NA | NR | |
| R | 4 (18.2) | 9 (40.9) | 2 (9.1) | 14 (63.6) | 8 (36.4) | 19 (86.4) | 16 (72.7) | 9 (40.9) | 11 (4.5) | |||
| S | 17 (89.5) | 13 (68.4) | 16 (84.2) | 15 (78.9) | 6 (31.6) | 16 (84.2) | 12 (63.2) | |||||
| I | 0 | 1 (5.3) | NR | NR | 2 (10.5) | NR | NR | 1 (5.3) | 3 (15.8) | 2 (10.5) | 2 (10.5) | |
| R | 2 (10.5) | 5 (26.3) | 1 (5.3) | 3 (15.3) | 10 (52.6) | 1 (5.3) | 5 (26.3) | |||||
| S | 4 (100.0) | 4 (100) | 3 (75.0) | 4 (100) | 4 (100) | 1 (25) | 1 (25) | 4 (100) | 2 (50) | |||
| I | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | NR | |
| R | 0 | 0 | 1 (25.0) | 0 | 0 | 3 (75) | 3 (75) | 0 | 2 (50) | |||
| S | 2 (100.0) | 0 | 1 (50.0) | 2 (100.0) | 2 (100.0) | 0 | 0 | 2 (100.0) | 1 (50) | |||
| I | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | NR | |
| R | 0 | 2 (100.0) | 1 (50.0) | 0 | 0 | 2 (100.0 | 2 (100.0) | 0 | 1 (50) | |||
| S | 93 (86.0) | 49 (45.4) | 52 (81.3) | 23 (35.9) | 60 (72.3) | 13 (20.3) | 18 (28.1) | 84 (77.8) | 38 (45.8) | 33 (75.0) | 28 (63.6) | |
| I | 1 (0.9) | 9 (8.3) | 2 (3.1) | 10 (15.6) | 6 (7.2) | 8 (12.5) | 5 (7.8) | 1 (0.9) | 5 (6.0) | 6 (13.6) | 4 (9.1) | |
| R | 14 (13.0) | 50 (46.3) | 9 (15.6) | 31 (48.4) | 17 (20.5) | 43 (67.2) | 41 (64.0) | 23 (21.3) | 40 (48.2) | 5 (11.4) | 12 (27.3) | |
NA Not applied, NR Not recommended, AUG Augmentin, CAZ Ceftazidime, CXT Cefoxitin, AMP Ampicillin, CEF Cefepime, TAT Tetracycline, CTR Ceftriaxone, CPR Ciprofloxacin, GN Gentamycin, IMP Imipenem, COT Cotrimoxazole, S Sensitivity, I Intermediate, R Resistance
multi-drug resistant rates of bacterial isolates among adult patient with lower respiratory tract infection at HUCSH, 2019
| Isolate | R0(%) | R1(%) | R2(%) | R3(%) | R4(%) | R5(%) | ≥R6(%) | Total (%) |
|---|---|---|---|---|---|---|---|---|
| 3 (8.3) | 7 (19.4) | 13 (36.1) | 7 (19.4) | 3 (8.3) | 2 (5.6) | 0 | 12 (33.3) | |
| 3 (14) | 2 (9.5) | 4 (19.0) | 6 (28.6) | 3 (14.3) | 2 (9.5) | 1 (4.7) | 12 (57.1) | |
| 3 (13.6) | 3 (13.6) | 4 (18.2) | 3 (13.6) | 3 (16.6) | 0 | 6 (27.3) | 12 (54.5) | |
| 4 (16.0) | 7 (28.0) | 10 (40.0) | 4 (16.0) | 0 | 0 | 0 | 4 (16.0) | |
| 6 (31.6) | 5 (26.3) | 6 (31.6) | 2 (10.5) | 0 | 0 | 0 | 2 (10.5) | |
| 2 (22.2) | 5 (55.5) | 1 (11.1) | 1 (11.1) | 0 | 0 | 1 (11.1) | ||
| 0 | 1 (25.0) | 2 (50.0) | 1 (25.0) | 0 | 0 | 0 | 1 (25.0) | |
| 3 (100) | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 0 | 0 | 1 (50.0) | 1 (50.0) | 0 | 0 | 0 | 1 (50.0) | |
| 0 | 0 | 0 | 0 | 1 (100) | 0 | 0 | 1 (100) | |
| Total ( | 24 (17.0) | 30 (21.1) | 41 (28.9) | 25 (17.6) | 10 (7.0) | 4 (2.8) | 7 (4.9) | 46/142 (32.4) |
Key: R0 No antibiotic resistance, R1 Resistance to one, R2 Resistance to two, R3 Resistance to three, R4 Resistance to four, R5 Resistance to five, and ≥ R6 Resistance to six and more than six antibiotics families